BrightInsight, a Flex Company, provides the leading global regulated digital health platform for biopharma and medtech. Our medical-grade Internet of Things (IoT) platform is built under a Quality Management System to support and optimize regulated drugs, devices and software through integrated data and actionable insights to enable customers to drive increased patient adherence and engagement.
The BrightInsight™ Platform uses software and services to capture, transmit and analyze data from CE-marked and FDA-regulated medical devices, combination products, apps and Software as a Medical Device, in compliance with security, privacy and regulatory requirements.
Ieso Digital Health is a biotechnology company whose mission it is to harness advanced technology and clinical science to deepen the understanding of the causes, symptoms and treatments of mental health problems.
By delivering psychological care to patients using the Ieso online therapy platform, a combination of data science, and advanced analytics can be used to develop digital therapeutics, education and training, and AI tools, to change the way mental healthcare is delivered across the world.
Ieso’s employees are dedicated to building a new paradigm in mental health science; building a complete understanding of the root causes of mental health conditions and developing interventions that will address the personal, societal and economic impacts of mental illness, paving the way for a world where everyone has access to the help they need, when they need it.
TopLine Power® is what Simon-Kucher is all about. We help clients grow revenue through optimization of strategy, pricing, marketing, and sales across industries.
We are a thought leader in these topics at the intersection of digitalization and life sciences, positioning our clients thrive in the healthcare industry of the future.
IQVIA (NYSE:IQV) is a leading global provider of information, innovative technology solutions and contract research services focused on helping healthcare clients find better solutions for patients. Formed through the merger of IMS Health and Quintiles, IQVIA applies Human Data Science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes.
Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes.
Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults.
JAZZ Venture Partners invests in companies that extend the boundaries of human performance — improving how we live, learn, work, play, and experience the world.
We seek breakthroughs at the intersection of digital technology and neuroscience that are influencing the human experience, such as augmented reality, artificial intelligence, immersive gaming, and closed-loop human-computer systems.
Our portfolio companies are unlocking human potential in health, mind-body wellness, accelerated learning and training, sports, entertainment, and the enterprise.
Cognoa’s digital diagnostics and personalized therapeutics improve the timeliness, scale, and effectiveness of behavioral healthcare. Their first clinically-validated mobile application identified autism on average 13 months earlier than the national average and as early as 18 months – when early intervention has the greatest potential for improved life-long outcomes.